Last update: Jan. 29, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
1st-generation-antihistamine and piperidine-type drug with a minimal sedative effect.
Indicated on prophylaxis of asthma, rhinitis (oral administration) and conjunctivitis (administrated as eye drops).
At latest update relevant published data on excretion into breast milk were not found.
Pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely that significant amounts of milk would pass through breastmilk.
Plasma levels following ophthalmic administration are undetectable (AEMPS 2011).
It is a medicine authorized for use in infants from 6 months of age on.
It does not influence prolactin levels (Dolecek 1984).
Until more published data on this drug related to breastfeeding is available, a safer and known alternative should be preferred during the neonatal period and in case of prematurity.
Ophthalmic administration is safe while breastfeeding.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM